Summary

The Immuno-oncology Assay Market is projected to reach USD 12,406.18 Million by 2035, growing at a CAGR of 10.92% from 2025 to 2035. The North American immuno-oncology assay market is changing and growing because of the increased number of cancer cases, the use of immunotherapy, and the investment in research & development.

Global Cancer Burden and Rising Incidence
The global incidence of cancer is going up mainly because of the aging population, urbanization, lifestyle changes, and the environment. By the period from 2022 to 2025, Asia will have the greatest number of newly diagnosed cases, which is expected to reach 9.83 million. Europe will be the second (4.47M), and North America the third (2.85M) region to have the highest number of new cancer cases.

Market Segmentation Overview
By Product:
- Reagents & Kits: Essential for biomarker detection workflows.
- Instruments: Advanced platforms for precise assay measurement.
By Assay Type:
- Immune Cell Profiling Assays: Characterize immune cells in detail.
- Cytokine Release Assays: Measures immune signaling molecule release.
- Tumor Mutation Burden Assays: Identify mutation load in tumors.
- Co-Culture Assays: Studies cell?cell interactions effectively.
- Cytotoxicity Assays: Evaluates immune-mediated cell killing.
- Others: Miscellaneous immuno-oncology research assays.
By Technology:
- ELISA: Detects proteins with high specificity.
- Flow Cytometry: Profiles cells via fluorescence markers.
- PCR-based Techniques: Amplify DNA for mutation detection.
- Next-Generation Sequencing (NGS): High-throughput genomic analysis.
- Mass Cytometry: Combines mass spectrometry with cytometry.
- Others: Additional emerging assay technologies.
By Application:
- Cancer Diagnosis: Early and accurate tumor detection.
- Therapeutic Monitoring: Tracks treatment responses effectively.
- Patient Stratification: Guides personalized therapy decisions.
- Clinical Trials: Supports drug development research.
By Indication:
- Lung Cancer: Targeted diagnostics and monitoring solutions.
- Colorectal Cancer: Immuno-oncology assays for therapy guidance.
- Melanoma: Advanced assays for immune response study.
- Ovarian Cancer: Detection and monitoring of disease.
- Breast Cancer: Biomarker-driven personalized treatment support.
- Others: Additional cancer types under study.
By End User:
- Hospitals & Clinics: Routine diagnostic and patient care.
- Pharmaceutical & Biotech Companies: Supports drug discovery and research.
- CROs: Outsourced clinical trial assay services.
- Others: Academic and research institutions' usage.

Regional Perspective
Immuno-oncology is the fastest-growing assay market in the US with a 42% share. The European market follows with a rate of 30%. The two regions of Asia-Pacific and MEA have the potential for huge growth due to the increasing number of cancer cases, the advancement of healthcare systems, and immunotherapy becoming more accessible.

Strategic Growth Driven by Aging Demographics
The global aged population that is rapidly expanding is a main point that explains the rising demand for precision-based immune-oncology assays, as older adults are more prone to cancer and thus require diagnostic methods that are biomarker-driven and personalized. Aging trends are becoming more prominent in areas such as Europe and Latin America.

Key Report Attributes
- Market Size 2024: USD 3,954.87 Million
- Market Size 2035: USD 12,406.18 Million
- CAGR (2025-2035): 10.92%
- Base Year: 2025
- Market Forecast Period: 2025-2035

Industry Segmentations Growth
- By Product: Reagents & Kits - 10.36%, Instruments - 12.07%.
- By Assay Type: Immune Cell Profiling Assays - 11.95%, Cytokine Release Assays - 9.54%.
- By Technology: Enzyme-Linked Immunosorbent Assay - 8.64%, Flow Cytometry - 10.90%.
- By Application: Cancer Diagnosis - 10.60%, Therapeutic Monitoring - 9.42%.
- By Indication: Lung Cancer - 12.03%, Colorectal Cancer - 7.18%.
- By End User: Hospitals & Clinics -10.93%, Pharmaceutical & Biotechnology Companies - 10.17%.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ............ 21
2 MARKET INTRODUCTION .......... 23
2.1 DEFINITION ........ 23
2.2 SCOPE OF THE STUDY ........... 23
2.3 RESEARCH OBJECTIVE .......... 23
2.4 MARKET STRUCTURE ........... 23
3 RESEARCH METHODOLOGY ........... 24
3.1 OVERVIEW ......... 24
3.2 DATA FLOW ....... 26
3.2.1 DATA MINING PROCESS .......... 26
3.3 PURCHASED DATABASE: ............. 27
3.4 SECONDARY SOURCES: ........ 28
3.4.1 SECONDARY RESEARCH DATA FLOW: ........... 29
3.5 PRIMARY RESEARCH: ........... 30
3.5.1 PRIMARY RESEARCH DATA FLOW: ........ 31
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED .......... 32
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ....... 32
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ............. 33
3.6.1 REVENUE ANALYSIS APPROACH ............ 33
3.7 DATA FORECASTING............. 34
3.7.1 DATA FORECASTING TYPE ....... 34
3.8 DATA MODELING ........... 35
3.8.1 MICROECONOMIC FACTOR ANALYSIS: .......... 35
3.8.2 DATA MODELING: ............. 36
3.9 TEAMS AND ANALYST CONTRIBUTION ....... 38
4 MARKET DYNAMICS ........... 40
4.1 INTRODUCTION ....... 40
4.2 DRIVERS ....... 40
4.2.1 RISING INCIDENCE OF CANCER ....... 40
4.2.2 GOVERNMENT AND PRIVATE FUNDING FOR CANCER RESEARCH ............. 41
4.3 RESTRAINTS ....... 42
4.3.1 HIGH COST OF IMMUNO-ONCOLOGY ASSAYS ....... 42
4.3.2 LACK OF SKILLED WORKFORCE ....... 42
4.4 OPPORTUNITY ......... 43
4.4.1 GROWING GERIATRIC POPULATION ....... 43
4.4.2 TECHNOLOGICAL ADVANCEMENTS ....... 44
5 MARKET FACTOR ANALYSIS ........... 45
5.1 PORTER'S FIVE FORCES MODEL ....... 45
5.1.1 THREAT OF NEW ENTRANTS ........... 45
5.1.2 BARGAINING POWER OF SUPPLIERS ............. 46
5.1.3 THREAT OF SUBSTITUTES ....... 46
5.1.4 BARGAINING POWER OF BUYERS ........... 46
5.1.5 INTENSITY OF RIVALRY ........... 46
5.2 IMPACT OF COVID-19 ON THE GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET............ 47
6 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT........... 50
6.1 OVERVIEW ......... 50
6.2 REAGENTS & KITS ........... 52
6.3 INSTRUMENTS .......... 53
7 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE ............. 54
7.1 OVERVIEW ......... 54
7.2 IMMUNE CELL PROFILING ASSAYS ......... 57
7.3 CYTOKINE RELEASE ASSAYS ............. 57
7.4 TUMOR MUTATION BURDEN ASSAYS ........... 58
7.5 CO-CULTURE ASSAYS ........... 58
7.6 CYTOTOXICITY ASSAYS ....... 59
7.7 OTHERS ........ 59
8 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY .......... 60
8.1 OVERVIEW ......... 60
8.2 ENZYME-LINKED IMMUNOSORBENT ASSAY ............ 63
8.3 FLOW CYTOMETRY ........ 63
8.4 PCR-BASED TECHNIQUES ........... 64
8.5 NEXT-GENERATION SEQUENCING (NGS) ............ 64
8.6 MASS CYTOMETRY ......... 65
8.7 OTHERS ........ 65
9 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION ............ 66
9.1 OVERVIEW ......... 66
9.2 CANCER DIAGNOSIS....... 68
9.3 THERAPEUTIC MONITORING ........... 69
9.4 PATIENT STRATIFICATION ......... 69
9.5 CLINICAL TRIALS ............ 70
10 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION ........ 71
10.1 OVERVIEW ......... 71
10.2 LUNG CANCER .......... 74
10.3 COLORECTAL CANCER ......... 75
10.4 MELANOMA ....... 75
10.5 OVARIAN CANCER ......... 76
10.6 BREAST CANCER ............. 76
10.7 OTHERS ........ 77
11 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER .......... 78
11.1 OVERVIEW ......... 78
11.2 HOSPITALS & CLINICS .......... 80
11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ......... 81
11.4 CONTRACT RESEARCH ORGANIZATIONS (CROS) ........... 81
11.5 OTHERS ........ 82
12 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY REGION ....... 83
12.1 OVERVIEW ......... 83
12.2 NORTH AMERICA ........... 84
12.2.1 US........ 90
12.2.2 CANADA ............ 93
12.3 EUROPE ........ 96
12.3.1 GERMANY .......... 101
12.3.2 FRANCE ............. 104
12.3.3 UK ....... 107
12.3.4 ITALY .......... 110
12.3.5 SPAIN ......... 113
12.3.6 RUSSIA ....... 116
12.3.7 REST OF EUROPE ....... 119
12.4 ASIA-PACIFIC ............ 122
12.4.1 CHINA ......... 128
12.4.2 INDIA .......... 131
12.4.3 JAPAN ........ 134
12.4.4 SOUTH KOREA ........... 137
12.4.5 MALAYSIA ......... 140
12.4.6 THAILAND .......... 143
12.4.7 INDONESIA ......... 146
12.4.8 REST OF ASIA-PACIFIC ............ 149
12.5 SOUTH AMERICA ............ 152
12.5.1 BRAZIL ........ 157
12.5.2 MEXICO ............. 160
12.5.3 ARGENTINA ....... 163
12.5.4 REST OF SOUTH AMERICA ....... 167
12.6 MIDDLE EAST AND AFRICA ........ 170
12.6.1 GCC COUNTRIES........ 175
12.6.2 SOUTH AFRICA .......... 178
12.6.3 REST OF MIDDLE EAST AND AFRICA ....... 181
13 COMPETITIVE LANDSCAPE ............. 186
13.1 INTRODUCTION ....... 186
13.2 MARKET SHARE ANALYSIS, 2024 ............. 186
13.3 COMPETITOR DASHBOARD ....... 187
13.4 PUBLIC PLAYERS STOCK SUMMARY ............. 188
13.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ......... 188
13.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ....... 189
13.6.1 PRODUCT LAUNCH ........... 189
13.6.2 PARTNERSHIP ........... 189
13.6.3 RECOGNITION ........... 190
13.6.4 ACQUISITION ............ 190
13.6.5 INTEGRATION ........... 190
13.6.6 STRATEGIC INNOVATION ......... 191
14 COMPANY PROFILES ......... 192
14.1 THERMO FISHER SCIENTIFIC INC. .......... 192
14.1.1 COMPANY OVERVIEW ....... 192
14.1.2 FINANCIAL OVERVIEW ............. 193
14.1.3 PRODUCTS OFFERED ........ 194
14.1.4 KEY DEVELOPMENTS ........ 195
14.1.5 SWOT ANALYSIS ....... 196
14.1.6 KEY STRATEGIES ....... 196
14.2 QIAGEN ........ 197
14.2.1 COMPANY OVERVIEW ....... 197
14.2.2 FINANCIAL OVERVIEW ............. 198
14.2.3 PRODUCTS OFFERED ........ 198
14.2.4 KEY DEVELOPMENTS ........ 199
14.2.5 SWOT ANALYSIS ....... 200
14.2.6 KEY STRATEGIES ....... 200
14.3 MERCK KGAA ........... 201
14.3.1 COMPANY OVERVIEW ....... 201
14.3.2 FINANCIAL OVERVIEW ............. 202
14.3.3 PRODUCTS OFFERED ........ 203
14.3.4 KEY DEVELOPMENTS ........ 203
14.3.5 SWOT ANALYSIS ....... 203
14.3.6 KEY STRATEGIES ....... 204
14.4 SARTORIUS AG ......... 205
14.4.1 COMPANY OVERVIEW ....... 205
14.4.2 FINANCIAL OVERVIEW ............. 206
14.4.3 PRODUCTS OFFERED ........ 206
14.4.4 KEY DEVELOPMENTS ........ 207
14.4.5 KEY STRATEGIES ....... 207
14.7 F. HOFFMANN-LA ROCHE LTD. ........ 215
14.7.1 COMPANY OVERVIEW ....... 215
14.7.2 FINANCIAL OVERVIEW ............. 216
14.7.3 PRODUCTS OFFERED ........ 217
14.7.4 KEY DEVELOPMENTS ........ 217
14.7.5 SWOT ANALYSIS ....... 218
14.7.6 KEY STRATEGIES ....... 218
14.8 AGILENT TECHNOLOGIES INC. ......... 219
14.8.1 COMPANY OVERVIEW ....... 219
14.8.2 FINANCIAL OVERVIEW ............. 220
14.8.3 PRODUCTS OFFERED ........ 221
14.8.4 KEY DEVELOPMENTS ........ 221
14.8.5 SWOT ANALYSIS ....... 222
14.8.6 KEY STRATEGIES ....... 223
14.9 ILLUMINA, INC. ........ 224
14.9.1 COMPANY OVERVIEW ....... 224
14.9.2 FINANCIAL OVERVIEW ............. 225
14.9.3 PRODUCTS OFFERED ........ 226
14.9.4 KEY DEVELOPMENTS ........ 226
14.9.5 KEY STRATEGIES ....... 226
14.10 AXION BIOSYSTEMS, INC ............ 227
14.10.1 COMPANY OVERVIEW ....... 227
14.10.2 FINANCIAL OVERVIEW ............. 228
14.10.3 PRODUCTS OFFERED ........ 228
14.10.4 KEY DEVELOPMENTS ........ 229
14.10.5 KEY STRATEGIES ....... 229
15 DATA CITATIONS ......... 230

ページTOPに戻る

List of Tables/Graphs

LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 37
TABLE 2 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION) 51
TABLE 3 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR REAGENTS & KITS, BY REGION, 2019–2035 (USD MILLION) 52
TABLE 4 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR INSTRUMENTS, BY REGION, 2019–2035 (USD MILLION) 53
TABLE 5 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION) 56
TABLE 6 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR IMMUNE CELL PROFILING ASSAYS, BY REGION, 2019–2035 (USD MILLION) 57
TABLE 7 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR CYTOKINE RELEASE ASSAYS, BY REGION, 2019–2035 (USD MILLION) 57
TABLE 8 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR TUMOR MUTATION BURDEN ASSAYS, BY REGION, 2019–2035 (USD MILLION)
58
TABLE 9 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR CO-CULTURE ASSAYS, BY REGION, 2019–2035 (USD MILLION) 58
TABLE 10 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR CYTOTOXICITY ASSAYS, BY REGION, 2019–2035 (USD MILLION) 59
TABLE 11 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD MILLION) 59
TABLE 12 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 62
TABLE 13 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2019–2035 (USD
MILLION) 63
TABLE 14 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR FLOW CYTOMETRY, BY REGION, 2019–2035 (USD MILLION) 63
TABLE 15 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR PCR-BASED TECHNIQUES, BY REGION, 2019–2035 (USD MILLION) 64
TABLE 16 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2019–2035 (USD MILLION)
64
TABLE 17 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR MASS CYTOMETRY, BY REGION, 2019–2035 (USD MILLION) 65
TABLE 18 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD MILLION) 65
TABLE 19 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 67
TABLE 20 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR CANCER DIAGNOSIS, BY REGION, 2019–2035 (USD MILLION) 68
TABLE 21 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR THERAPEUTIC MONITORING, BY REGION, 2019–2035 (USD MILLION) 69
TABLE 22 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR PATIENT STRATIFICATION, BY REGION, 2019–2035 (USD MILLION) 69
TABLE 23 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR CLINICAL TRIALS, BY REGION, 2019–2035 (USD MILLION) 70
TABLE 24 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION) 73
TABLE 25 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR LUNG CANCER, BY REGION, 2019–2035 (USD MILLION) 74
TABLE 26 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR COLORECTAL CANCER, BY REGION, 2019–2035 (USD MILLION) 75
TABLE 27 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR MELANOMA, BY REGION, 2019–2035 (USD MILLION) 75
TABLE 28 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR OVARIAN CANCER, BY REGION, 2019–2035 (USD MILLION) 76
TABLE 29 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR BREAST CANCER, BY REGION, 2019–2035 (USD MILLION) 76
TABLE 30 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD MILLION) 77
TABLE 31 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION) 79
TABLE 32 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR HOSPITALS & CLINICS, BY REGION, 2019–2035 (USD MILLION) 80
TABLE 33 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2035
(USD MILLION) 81
TABLE 34 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2019–2035 (USD
MILLION) 81
TABLE 35 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD MILLION) 82
TABLE 36 GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY REGION, 2019-2035 (USD MILLION) 83
TABLE 37 NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 86
TABLE 38 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 87
TABLE 39 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019-2035 (USD MILLION) 87
TABLE 40 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 88
TABLE 41 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 88
TABLE 42 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019-2035 (USD MILLION) 89
TABLE 43 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019-2035 (USD MILLION) 89
TABLE 44 US: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 90
TABLE 45 US: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019-2035 (USD MILLION) 90
TABLE 46 US: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 91
TABLE 47 US: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 91
TABLE 48 US: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019-2035 (USD MILLION) 92
TABLE 49 US: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019-2035 (USD MILLION) 92
TABLE 50 CANADA: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 93
TABLE 51 CANADA: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019-2035 (USD MILLION) 93
TABLE 52 CANADA: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 94
TABLE 53 CANADA: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 94
TABLE 54 CANADA: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019-2035 (USD MILLION) 95
TABLE 55 CANADA: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019-2035 (USD MILLION) 95
TABLE 56 EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 97
TABLE 57 EUROPE: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 98
TABLE 58 EUROPE: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019-2035 (USD MILLION) 98
TABLE 59 EUROPE: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 99
TABLE 60 EUROPE: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 99
TABLE 61 EUROPE: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019-2035 (USD MILLION) 100
TABLE 62 EUROPE: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019-2035 (USD MILLION) 100
TABLE 63 GERMANY: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 101
TABLE 64 GERMANY: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019-2035 (USD MILLION) 101
TABLE 65 GERMANY: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 102
TABLE 66 GERMANY: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 102
TABLE 67 GERMANY: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019-2035 (USD MILLION) 103
TABLE 68 GERMANY: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019-2035 (USD MILLION) 103
TABLE 69 FRANCE: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 104
TABLE 70 FRANCE: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019-2035 (USD MILLION) 104
TABLE 71 FRANCE: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 105
TABLE 72 FRANCE: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 105
TABLE 73 FRANCE: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019-2035 (USD MILLION) 106
TABLE 74 FRANCE: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019-2035 (USD MILLION) 106
TABLE 75 UK: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 107
TABLE 76 UK: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019-2035 (USD MILLION) 107
TABLE 77 UK: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 108
TABLE 78 UK: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 108
TABLE 79 UK: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019-2035 (USD MILLION) 109
TABLE 80 UK: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019-2035 (USD MILLION) 109
TABLE 81 ITALY: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 110
TABLE 82 ITALY: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019-2035 (USD MILLION) 110
TABLE 83 ITALY: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 111
TABLE 84 ITALY: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 111
TABLE 85 ITALY: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019-2035 (USD MILLION) 112
TABLE 86 ITALY: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019-2035 (USD MILLION) 112
TABLE 87 SPAIN: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 113
TABLE 88 SPAIN: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019-2035 (USD MILLION) 113
TABLE 89 SPAIN: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 114
TABLE 90 SPAIN: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 114
TABLE 91 SPAIN: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019-2035 (USD MILLION) 115
TABLE 92 SPAIN: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019-2035 (USD MILLION) 115
TABLE 93 RUSSIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 116
TABLE 94 RUSSIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019-2035 (USD MILLION) 116
TABLE 95 RUSSIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 117
TABLE 96 RUSSIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 117
TABLE 97 RUSSIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019-2035 (USD MILLION) 118
TABLE 98 RUSSIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019-2035 (USD MILLION) 118
TABLE 99 REST OF EUROPE: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 119
TABLE 100 REST OF EUROPE: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019-2035 (USD MILLION) 119
TABLE 101 REST OF EUROPE: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 120
TABLE 102 REST OF EUROPE: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 120
TABLE 103 REST OF EUROPE: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019-2035 (USD MILLION) 121
TABLE 104 REST OF EUROPE: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019-2035 (USD MILLION) 121
TABLE 105 ASIA-PACIFIC: IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 124
TABLE 106 ASIA-PACIFIC: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION) 125
TABLE 107 ASIA-PACIFIC: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION) 125
TABLE 108 ASIA-PACIFIC: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 126
TABLE 109 ASIA-PACIFIC: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 126
TABLE 110 ASIA-PACIFIC: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION) 127
TABLE 111 ASIA-PACIFIC: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION) 127
TABLE 112 CHINA: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION) 128
TABLE 113 CHINA: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION) 128
TABLE 114 CHINA: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 129
TABLE 115 CHINA: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 129
TABLE 116 CHINA: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION) 130
TABLE 117 CHINA: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION) 130
TABLE 118 INDIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION) 131
TABLE 119 INDIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION) 131
TABLE 120 INDIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 132
TABLE 121 INDIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 132
TABLE 122 INDIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION) 133
TABLE 123 INDIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION) 133
TABLE 124 JAPAN: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION) 134
TABLE 125 JAPAN: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION) 134
TABLE 126 JAPAN: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 135
TABLE 127 JAPAN: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 128 JAPAN: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION)
TABLE 129 JAPAN: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION)
TABLE 130 SOUTH KOREA: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION)
TABLE 131 SOUTH KOREA: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION)
TABLE 132 SOUTH KOREA: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 133 SOUTH KOREA: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 134 SOUTH KOREA: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION)
TABLE 135 SOUTH KOREA: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION)
TABLE 136 MALAYSIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION)
TABLE 137 MALAYSIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION)
TABLE 138 MALAYSIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 139 MALAYSIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 140 MALAYSIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION)
TABLE 141 MALAYSIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION)
TABLE 142 THAILAND: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION)
TABLE 143 THAILAND: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION)
TABLE 144 THAILAND: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 145 THAILAND: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 146 THAILAND: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION)
TABLE 147 THAILAND: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION)
TABLE 148 INDONESIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION)
TABLE 149 INDONESIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION)
TABLE 150 INDONESIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 151 INDONESIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 152 INDONESIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION)
TABLE 153 INDONESIA: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION)
TABLE 154 REST OF ASIA-PACIFIC: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION)
TABLE 155 REST OF ASIA-PACIFIC: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION)
TABLE 156 REST OF ASIA-PACIFIC: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 157 REST OF ASIA-PACIFIC: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 158 REST OF ASIA-PACIFIC: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION)
TABLE 159 REST OF ASIA-PACIFIC: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION)
TABLE 160 SOUTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2019–2035 (USD MILLION)
TABLE 161 SOUTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION)
TABLE 162 SOUTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION)
TABLE 163 SOUTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 164 SOUTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 165 SOUTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION)
TABLE 166 SOUTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION)
TABLE 167 BRAZIL: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION)
TABLE 168 BRAZIL: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION)
TABLE 169 BRAZIL: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 170 BRAZIL: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 171 BRAZIL: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION)
TABLE 172 BRAZIL: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION)
TABLE 173 MEXICO: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION)
TABLE 174 MEXICO: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION)
TABLE 175 MEXICO: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 176 MEXICO: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 177 MEXICO: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION)
TABLE 178 MEXICO: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION)
TABLE 179 ARGENTINA: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION)
TABLE 180 ARGENTINA: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION)
TABLE 181 ARGENTINA: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 182 ARGENTINA: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 183 ARGENTINA: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION)
TABLE 184 ARGENTINA: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION)
TABLE 185 REST OF SOUTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION)
TABLE 186 REST OF SOUTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION)
TABLE 187 REST OF SOUTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 188 REST OF SOUTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 189 REST OF SOUTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION)
TABLE 190 REST OF SOUTH AMERICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION)
TABLE 191 MIDDLE EAST AND AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2019–2035 (USD MILLION)
TABLE 192 MIDDLE EAST AND AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION)
TABLE 193 MIDDLE EAST AND AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION)
TABLE 194 MIDDLE EAST AND AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 195 MIDDLE EAST AND AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 196 MIDDLE EAST AND AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION)
TABLE 197 MIDDLE EAST AND AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION)
TABLE 198 GCC COUNTRIES: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION)
TABLE 199 GCC COUNTRIES: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION)
TABLE 200 GCC COUNTRIES: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 201 GCC COUNTRIES: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 202 GCC COUNTRIES: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION)
TABLE 203 GCC COUNTRIES: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION)
TABLE 204 SOUTH AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION)
TABLE 205 SOUTH AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION)
TABLE 206 SOUTH AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 207 SOUTH AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 208 SOUTH AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION)
TABLE 209 SOUTH AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION)
TABLE 210 REST OF MIDDLE EAST AND AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2019–2035 (USD MILLION)
TABLE 211 REST OF MIDDLE EAST AND AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY ASSAY TYPE, 2019–2035 (USD MILLION)
TABLE 212 REST OF MIDDLE EAST AND AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 213 REST OF MIDDLE EAST AND AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 214 REST OF MIDDLE EAST AND AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2019–2035 (USD MILLION)
TABLE 215 REST OF MIDDLE EAST AND AFRICA: IMMUNO-ONCOLOGY ASSAY MARKET, BY END USER, 2019–2035 (USD MILLION)
TABLE 216 PRODUCT LAUNCH
TABLE 217 PARTNERSHIP/COLLABORATION
TABLE 218 AGREEMENT
TABLE 219 ACQUISITION/EXPANSION
TABLE 220 INTEGRATION
TABLE 221 STRATEGIC INNOVATION
TABLE 222 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 223 QIAGEN: PRODUCTS OFFERED
TABLE 224 QIAGEN: KEY DEVELOPMENTS
TABLE 225 MERCK KGAA: PRODUCTS OFFERED
TABLE 226 SARTORIUS AG: PRODUCTS OFFERED
TABLE 227 SARTORIUS AG: KEY DEVELOPMENTS
TABLE 229 BIO-TECHNE: PRODUCTS OFFERED
TABLE 230 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
TABLE 231 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
TABLE 232 AGILENT TECHNOLOGIES INC.: PRODUCTS OFFERED
TABLE 233 AGILENT TECHNOLOGIES INC.: PRODUCTS OFFERED
TABLE 234 ILLUMINA, INC.: PRODUCTS OFFERED
TABLE 235 ILLUMINA, INC.: PRODUCTS OFFERED
TABLE 236 AXION BIOSYSTEMS, INC.: PRODUCTS OFFERED
TABLE 237 AXION BIOSYSTEMS, INC.: KEY DEVELOPMENTS